Drugs / Pegylated Interferon-alpha
Pegylated Interferon-alpha
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT00196638 | May 2002 → Mar 2006 | HIV infectious disease | French National Agency for Research on AIDS and Viral Hepatitis | Terminated | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT06923280 | May 2025 → Dec 2027 expected | chronic hepatitis B virus infection | Huashan Hospital | Not yet recruiting | No outcome recorded |
| — | NCT00687999 | Dec 2005 → Jun 2008 | chronic hepatitis C virus infection | Kaohsiung Medical University Chung-Ho Memorial Hospital | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 1 | NCT00277758 Background | Mar 2004 → Jul 2006 | hepatitis C virus infection | Weill Medical College of Cornell University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00984620 Background | Sep 2009 → Apr 2011 | hepatitis C virus infection | Boehringer Ingelheim | Completed | Missed primary |
| Phase 3 | NCT01358864 Background | Jun 2011 → Feb 2013 | chronic hepatitis C virus infection | Boehringer Ingelheim | Completed | Met primary |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pegylated interferon-alpha | “Ribavirin + Pegylated interferon-alpha” NCT00277758 ↗ |
| Known as | IFN | “Pegylated Interferon-alpha (IFN)” NCT01358864 ↗1“Pegylated Interferon-alpha (IFN)” NCT00984620 ↗ |
| Known as | PEG-IFN-alpha | “PEG-IFN-alpha” NCT00687999 ↗ |
| Modality | Protein / enzyme biologic | “a cytokine, interferon alpha” NCT00196638 ↗ |
| Route | Subcutaneous | “Pegylated-Interferon-alpha 1.5 ug/kg weekly subcutaneously.” NCT00277758 ↗ |